RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
The RNAi for Developing Targeted Therapeutics meeting, held in Boston, included topics covering new therapeutic developments in the field of RNAi-based drug discovery. This conference report highlights selected presentations on the reversal of drug resistance using targeted siRNA or small-hairpin RNA and EnGeneIC drug delivery vehicles, the development of siRNA therapeutics for lung diseases, siRNA-based topical microbicides, locked nucleic acid-based oligonucleotides, and company-specific approaches to the development of RNAi therapeutics from Alnylam Pharmaceuticals Inc and MDRNA Inc. In addition to in vivo delivery approaches, novel RNAi-based approaches are also discussed, including dicer substrate siRNA, sd-rxRNA from RXi Pharmaceuticals Corp and a cationic liposome formulation of RNAi.
Plane
Guillaume
G
MitoProd, 146 rue Léo Saignat, Bordeaux 33076, France. contact@mitoprod.com
D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D004351:Drug Resistance; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000503:physiopathology; D009841:Oligonucleotides / Q000008:administration & dosage; D034741:RNA, Small Interfering / Q000008:administration & dosage*
D009841:Oligonucleotides; D034741:RNA, Small Interfering; C477371:locked nucleic acid